Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Int J Nanomedicine ; 15: 5839-5853, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32848393

RESUMO

BACKGROUND: The development of paclitaxel (PTX) resistance seriously restricts its clinical efficacy. An attractive option for combating resistance is inhibiting the expression of P-glycoprotein (P-gp) in tumor cells. We have reported that flavokawain A (FKA) inhibited P-gp protein expression in PTX-resistant A549 (A549/T) cells, indicating that FKA combined with PTX may reverse PTX resistance. However, due to the variable pharmacokinetics of FKA and PTX, the conventional cocktail combination in clinics may cause uncertainty of treatment efficacy in vivo. MATERIALS AND METHODS: To synergistically elevate the anti-cancer activity of PTX and FKA in vivo, the national medical products administration (NMPA) approved sodium aescinate (Aes) was utilized to stabilize hydrophobic PTX and FKA to form polymer-free twin like PTX-A nanoparticles (NPs) and FKA-A NPs. RESULTS: The resulting nanoparticles prepared simply by nanoprecipitation possessed similar particle size, good stability and ultrahigh drug loadings of up to 50%. With the aid of Aes, these two drugs accumulated in tumor tissue by passive targeting and were efficiently taken up by A549/T cells; this resulted in significant suppression of tumor growth in A549/T homograft mice at a low PTX dose (2.5 mg·kg-1). Synergistic effects and reversed PTX resistance were achieved by the combination of PTX-A NPs and FKA-A NPs by inhibiting P-gp expression in tumor cells. CONCLUSION: Using NMPA-approved Aes to prepare twin-like nanoparticles without introducing any new materials provides an efficient platform for combination chemotherapy and clinical translation.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia , Resistencia a Medicamentos Antineoplásicos/efeitos dos fármacos , Nanopartículas/química , Paclitaxel/farmacologia , Saponinas/química , Triterpenos/química , Células A549 , Animais , Protocolos de Quimioterapia Combinada Antineoplásica/química , Protocolos de Quimioterapia Combinada Antineoplásica/farmacocinética , Linhagem Celular Tumoral , Chalcona/administração & dosagem , Chalcona/análogos & derivados , Chalcona/farmacocinética , Estabilidade de Medicamentos , Sinergismo Farmacológico , Feminino , Humanos , Interações Hidrofóbicas e Hidrofílicas , Camundongos Endogâmicos BALB C , Nanopartículas/administração & dosagem , Nanopartículas/uso terapêutico , Paclitaxel/administração & dosagem , Paclitaxel/farmacocinética , Tamanho da Partícula , Polímeros/química , Ensaios Antitumorais Modelo de Xenoenxerto
2.
Acta Trop ; 98(1): 59-65, 2006 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-16529707

RESUMO

The present study was designed to investigate a new administration model and the antileishmanial activity of a semi-synthetic chalcone, benzylideneacetophenone (trans-chalcone). The antileishmanial activity of this product was first tested in vitro against promastigotes of L. braziliensis, L. tropica, L. infantum and L. amazonensis. An in vivo experiment was carried out using subcutaneous administration of trans-chalcone and implants of synthetic biodegradable polymers, polylactic acid (PLA) and polylactic/glycolic acid (PLGA). This compound showed potent inhibitory effects on the growth of all Leishmania strains examinated. Subcutaneous administration of trans-chalcone at a single dose of 4 mg/kg of body weight reduced lesion development in mice infected with L. amazonensis. A similar inhibition of the lesion growth in mice treated with trans-chalcone and pentamidine was observed. PLA and PGLA implants of trans-chalcone at 4 mg/kg were administered to mice infected with L. amazonensis. PLGA implants induced a highest reduction in the lesion size (31.25%) than PLA implants (10.75%). Treatment in vitro with trans-chalcone at IC50, completely inhibited the pathogenicity of this parasite in vivo. The development of this model provides a new practical technique for delivering drugs and can be useful for experimental leishmaniasis treatment.


Assuntos
Implantes Absorvíveis , Antiprotozoários/administração & dosagem , Antiprotozoários/uso terapêutico , Chalcona/administração & dosagem , Chalcona/uso terapêutico , Leishmaniose Cutânea/tratamento farmacológico , Animais , Quimioterapia Combinada , Ácido Láctico , Leishmania braziliensis , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Estrutura Molecular , Pentamidina/uso terapêutico , Poliésteres , Ácido Poliglicólico , Copolímero de Ácido Poliláctico e Ácido Poliglicólico , Polímeros , Fatores de Tempo
3.
Zhongguo Zhong Yao Za Zhi ; 31(14): 1147-50, 2006 Jul.
Artigo em Zh | MEDLINE | ID: mdl-17048580

RESUMO

OBJECTIVE: To prepare shuxiong micropellets. METHOD: Shuxiong micropellets were prepared by using a centrifugal granulator. The formulation composition and process factors were optimized investigated by adopting several indices such as size distribution, repose angle, bulk density and friability as indexes. RESULT: The optimal process parameters were as follows. The ratio of fine intermediate product and MCC was 3:1 (w/w), the adhesive agent was 3% HMPC solution, the rotating rate of plate was 200 r x min(-1), the blower rate was 15 x 20 L x min(-1), the rate of air flow was 15 L x min(-1), the spray air pressure was 0.5 MPa, the rotating of spray solution pump was 5-25 r x min(-1) and the rotating rate of powder feed machine was 5-25 r x min(-1). CONCLUSION: Under the optimal conditions, micropellets prepared by using centrifugal granulator hadpossessed prefect shape and surface characteristics and the yield of shuxiong pellets was 90.5%.


Assuntos
Chalcona/análogos & derivados , Ginsenosídeos/administração & dosagem , Fenóis/administração & dosagem , Plantas Medicinais/química , Quinonas/administração & dosagem , Tecnologia Farmacêutica/métodos , Carthamus tinctorius/química , Celulose , Centrifugação/métodos , Chalcona/administração & dosagem , Chalcona/isolamento & purificação , Combinação de Medicamentos , Excipientes , Ginsenosídeos/isolamento & purificação , Derivados da Hipromelose , Ligusticum/química , Metilcelulose/análogos & derivados , Microesferas , Panax notoginseng/química , Tamanho da Partícula , Fenóis/isolamento & purificação , Quinonas/isolamento & purificação
4.
Aust Dent J ; 42(5): 343-6, 1997 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-9409052

RESUMO

In the antimicrobial therapy of denture stomatitis, it is desirable to inhibit the growth of not only the primary causative organism, Candida albicans, but also other oral bacteria closely associated with the condition. Three synthetic anti-candidal chalcones were characterized and compared for their additional activity in inhibiting these causative bacteria. Among the tested chalcones, 2,4,2'-trihydroxy-5'-methylchalcone showed the highest activity for different Gram-positive bacteria. It inhibited the growth of streptococci, staphylococci and lactobacilli at 25.0-50.0 micrograms/mL which was lower than or comparable to its minimum inhibitory concentration for candida. It functioned with a bactericidal action and leaked 260 nm-absorbing substances from the streptococcal cells. The antimicrobial activity of 2,4,2'-trihydroxy-5'-methylchalcone against both primary and secondary causative agents suggests it could be useful as a potent therapeutic agent in denture stomatitis.


Assuntos
Anti-Infecciosos/farmacologia , Bactérias/efeitos dos fármacos , Candida albicans/efeitos dos fármacos , Chalcona/farmacologia , Estomatite sob Prótese/microbiologia , Antibacterianos , Anti-Infecciosos/administração & dosagem , Anti-Infecciosos/uso terapêutico , Bactérias/crescimento & desenvolvimento , Chalcona/administração & dosagem , Chalcona/análogos & derivados , Chalcona/uso terapêutico , Chalconas , Corantes , Escherichia coli/efeitos dos fármacos , Bactérias Gram-Positivas/efeitos dos fármacos , Humanos , Klebsiella pneumoniae/efeitos dos fármacos , Lacticaseibacillus casei/efeitos dos fármacos , Boca/microbiologia , Serratia marcescens/efeitos dos fármacos , Staphylococcus aureus/efeitos dos fármacos , Estomatite sob Prótese/tratamento farmacológico , Streptococcus/efeitos dos fármacos , Streptococcus mutans/efeitos dos fármacos
5.
Int J Nanomedicine ; 6: 985-91, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21720510

RESUMO

BACKGROUND: A microemulsion is an effective formulation for improving the oral bioavailability of poorly soluble drugs. In this paper, a water-in-oil (w/o) microemulsion was investigated as a system for enhancing the oral bioavailability of Biopharmaceutic Classification System (BCS) III drugs. METHODS: The microemulsion formulation was optimized using a pseudoternary phase diagram, comprising propylene glycol dicaprylocaprate (PG), Cremophor(®) RH40, and water (30/46/24 w/w). RESULTS: The microemulsion increased the oral bioavailability of hydroxysafflor yellow A which was highly water-soluble but very poorly permeable. The relative bioavailability of hydroxysafflor yellow A microemulsion was about 1937% compared with a control solution in bile duct-nonligated rats. However, the microemulsion showed lower enhanced absorption ability in bile duct-ligated rats, and the relative bioavailability was only 181%. In vitro experiments were further employed to study the mechanism of the enhanced effect of the microemulsion. In vitro lipolysis showed that the microemulsion was digested very quickly by pancreatic lipase. About 60% of the microemulsion was digested within 1 hour. Furthermore, the particle size of the microemulsion after digestion was very small (53.3 nm) and the digested microemulsion had high physical stability. An everted gut sac model demonstrated that cumulative transport of the digested microemulsion was significantly higher than that of the diluted microemulsion. CONCLUSION: These results suggested that digestion of the microemulsion by pancreatic lipase plays an important role in enhancing oral bioavailability of water-soluble drugs.


Assuntos
Chalcona/análogos & derivados , Sistemas de Liberação de Medicamentos/métodos , Quinonas/administração & dosagem , Quinonas/química , Administração Oral , Análise de Variância , Animais , Disponibilidade Biológica , Chalcona/administração & dosagem , Chalcona/química , Chalcona/farmacocinética , Preparações de Ação Retardada , Emulsões/administração & dosagem , Emulsões/química , Mucosa Intestinal/metabolismo , Lipase/química , Lipólise , Masculino , Tamanho da Partícula , Polietilenoglicóis/química , Propilenoglicóis/química , Quinonas/farmacocinética , Ratos , Ratos Wistar , Água
6.
Antimicrob Agents Chemother ; 43(7): 1776-8, 1999 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-10390243

RESUMO

The inhibition of intracellular Leishmania amazonensis growth by 2', 6'-dihydroxy-4'-methoxychalcone (DMC) isolated from Piper aduncum was further enhanced after encapsulation of DMC in polymeric nanoparticles. Encapsulated DMC also showed increased antileishmanial activity in infected BALB/c mice, as evidenced by significantly smaller lesions and fewer parasites in the lesions.


Assuntos
Antiparasitários/administração & dosagem , Chalcona/análogos & derivados , Leishmania/efeitos dos fármacos , Poliésteres/administração & dosagem , Animais , Chalcona/administração & dosagem , Chalconas , Sistemas de Liberação de Medicamentos , Feminino , Leishmaniose/tratamento farmacológico , Camundongos , Camundongos Endogâmicos BALB C
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA